DAWNZERA (AUTOINJECTOR) Drug Patent Profile

When do Dawnzera (autoinjector) patents expire, and when can generic versions of Dawnzera (autoinjector) launch?

Dawnzera (autoinjector) is a drug marketed by Ionis Pharms Inc and is included in one NDA. There are five patents protecting this drug.

This drug has three hundred and seven patent family members in forty countries.

The generic ingredient in DAWNZERA (AUTOINJECTOR) is donidalorsen sodium. One supplier is listed for this compound. Additional details are available on the donidalorsen sodium profile page.

DrugPatentWatch^® Generic Entry Outlook for Dawnzera (autoinjector)

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be May 1, 2034. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for DAWNZERA (AUTOINJECTOR)

International Patents:	307
US Patents:	5
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for DAWNZERA (AUTOINJECTOR)

DAWNZERA (AUTOINJECTOR) is protected by five US patents.

This potential generic entry date is based on patent 9,127,276.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ionis Pharms Inc	DAWNZERA (AUTOINJECTOR)	donidalorsen sodium	SOLUTION;SUBCUTANEOUS	219407-001	Aug 21, 2025		RX	Yes	Yes	10,294,477		Y	Y
Ionis Pharms Inc	DAWNZERA (AUTOINJECTOR)	donidalorsen sodium	SOLUTION;SUBCUTANEOUS	219407-001	Aug 21, 2025		RX	Yes	Yes	9,127,276			Y
Ionis Pharms Inc	DAWNZERA (AUTOINJECTOR)	donidalorsen sodium	SOLUTION;SUBCUTANEOUS	219407-001	Aug 21, 2025		RX	Yes	Yes	9,315,811

International Patents for DAWNZERA (AUTOINJECTOR)

When does loss-of-exclusivity occur for DAWNZERA (AUTOINJECTOR)?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

Chile

China

Costa Rica

Croatia

Cyprus

Denmark

Dominican Republic

Eurasian Patent Organization

European Patent Office

Finland

France

Hong Kong

Hungary

Israel

Japan

Lithuania

Malaysia

Mexico

Montenegro

Morocco

Netherlands

New Zealand

Norway

Peru

Philippines

Poland

Portugal

Russian Federation

San Marino

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering DAWNZERA (AUTOINJECTOR) around the world.

Country	Patent Number	Title	Estimated Expiration
San Marino	T201900316
Russian Federation	2018112167	КОМПОЗИЦИИ И СПОСОБЫ МОДУЛИРОВАНИЯ ЭКСПРЕССИИ АПОЛИПОПРОТЕИНА C-III
Norway	2026003

Supplementary Protection Certificates for DAWNZERA (AUTOINJECTOR)

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3524680	2025C/700	Belgium		PRODUCT NAME: EPLONTERSEN, OPTIONEEL IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; AUTHORISATION NUMBER AND DATE: EU/1/24/1875 20250306
3524680	301341	Netherlands		PRODUCT NAME: EPLONTERSEN, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/24/1875 20250307
3524680	28/2025	Austria		PRODUCT NAME: EPLONTERSEN, OPTIONAL IN DER FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES DAVON; REGISTRATION NO/DATE: EU/1/24/1875 (MITTEILUNG) 20250307

Investment Scenario, Market Dynamics, and Financial Trajectory for DAWNZERA (Autoinjector)

Last updated: February 3, 2026

Executive Summary

DAWNZERA, an autoinjector platform, shows promising growth potential in the pharmaceutical and medical devices sectors. Its success hinges on rising demand for self-injection solutions, technological innovation, regulatory pathways, and market positioning. This comprehensive analysis evaluates the current industry landscape, competitive positioning, financial forecasts, and investment considerations associated with DAWNZERA.

---

1. Industry Overview and Market Penetration

Global Autoinjector Market Outlook

Parameter	2022 Estimate	2027 Forecast	CAGR (Compound Annual Growth Rate)	Source
Market Size (USD billion)	$8.5	$15.3	12.2%	[1], [2]
Key Drivers	Chronic diseases, self-administration, COVID-19
Major Segments	Autoimmune, allergy, multiple sclerosis, others

Drivers of Market Growth

• Chronic Disease Management: Increasing prevalence of rheumatoid arthritis, multiple sclerosis, and diabetes drives demand for patient-friendly delivery devices.
• Self-Administration Preference: Regulatory encouragement and technological advances reduce reliance on healthcare facilities.
• COVID-19 Impact: Accelerated adoption of autoinjectors during pandemic-related healthcare access limitations.

Market Segmentation

Segment	Market Share (2022)	Projected Share (2027)	Key Players
Autoimmune Diseases	45%	55%	Zealand Pharma, DMRH, Amgen
Allergies	25%	15%	Mylan, Alvogen
Multiple Sclerosis	15%	20%	Biogen, Teva
Others	15%	10%	Various smaller entities

---

2. Competitive Landscape and Differentiation

Key Competitors

Company	Product Portfolio	Market Position	Notable Features
Amgen	EpiPen, Amgen Autoinjectors	Market leader in allergy autoinjectors	Established distribution, brand recognition
Zealand Pharma	ZJAB (ZaZ) Autoinjector	Innovative delivery systems	Ease-of-use, patient comfort
Mylan	EpiPen, generic auto-injectors	Cost-effective alternatives	Price-sensitive markets
Biogen	Plegridy (immune therapy autoinjector)	Specialty neuroimmunology	Precision, customization

Differentiation Factors for DAWNZERA

Feature	Industry Norm	DAWNZERA Advantage
Needle-less Auto-insertion	Varies	Advanced autoinjector with minimal needle exposure
Ease of Use	Standardized by design	Intuitive interface, ergonomic design
Connectivity	Emerging feature in market	Integration with digital health apps
Manufacturing Scale	Fragmented	Planned scale, potential for large-scale production

---

3. Regulatory Pathways & Approval Strategies

Region	Regulatory Body	Approvals Needed	Timeline (Months)	Remarks
United States	FDA (Food & Drug Admin)	Premarket Approval (PMA), 510(k)	12-36	Device-specific classification; breakthrough device designation possible
European Union	EMA & Notified Bodies	CE Marking	9-24	Harmonized standards under MDR; fast-track options available
Japan	PMDA	Pharmaceutical Affairs Law (PAL)	12-24	Emphasizes post-market surveillance

Key Regulatory Challenges

• Demonstrating device safety and efficacy.
• Conforming to biocompatibility and manufacturing standards (ISO 13485).
• Navigating post-approval monitoring and real-world evidence collection.

---

4. Financial Trajectory & Investment Outlook

Initial Investment & R&D Costs

Item	Estimated Amount (USD Million)	Purpose
Research & Development	$25 - $50	Prototyping, testing, clinical validation
Regulatory Submission	$10 - $20	Documentation, filings, audits
Manufacturing Setup	$20 - $40	Scale-up, Quality Control

Projected Revenue Streams

Revenue Source	2023	2024	2025	2026	2027	Compound Growth Rate
Device Sales	$10M	$50M	$150M	$300M	$500M	60% CAGR
Licensing & Partnerships	$5M	$12M	$25M	$50M	$80M	70% CAGR
Digital & Service Modules	$0.5M	$2M	$7M	$15M	$25M	75% CAGR

Break-Even Analysis

• Expected break-even point: Year 3 (approx. 2025) with cumulative revenues surpassing total investment plus operational costs.
• Sensitivities: Market acceptance, pricing, regulatory delays, reimbursement landscape.

Potential Valuation Estimates

Valuation Metric	2023	2024	2025	2026	2027	Notes
Price-to-Sales (P/S) Ratio	5x	4.5x	4x	3.8x	3.5x	Reflects high growth and market optimism
Estimated Company Valuation	$150M	$250M	$600M	$1.2B	$2.3B	Based on projected revenues and industry multiples

---

5. Investment Risks and Mitigation Strategies

Risk Factor	Description	Mitigation Measures
Regulatory Delays	Lengthening approval timelines	Early engagement with authorities, robust clinical data
Market Penetration Challenges	Competition from established brands	Differentiation, strategic alliances
Manufacturing & Supply Chain	Disruptions affecting scale-up	Multiple supplier agreements, inventory planning
Reimbursement & Pricing	Payer resistance to premium device pricing	Early health economics studies, payer engagement
Technological Obsolescence	Rapid innovation rendering product outdated	Continuous R&D, digital health integration

---

6. Comparative Market and Technology Assessment

Device Type	Current Innovations	Market Share (2022)	Future Trends
Traditional Autoinjectors	Mechanical spring-based devices	~60%	Smart devices, connectivity
Electronic Autoinjectors	Incorporate digital feedback, connectivity	20%	Increasing adoption
DAWNZERA (Proposed)	Advanced autoinjector with digital and ergonomic features	N/A (startup)	Potential market disruptor

Technology Trends

• Integration of IoT (Internet of Things) features.
• Enhanced patient-centric design.
• Counteractive strategies against biosimilar competition.

---

7. Policies and Industry Trends Impacting DAWNZERA

Policy/Trend	Impact on DAWNZERA
Reimbursement Policies	Favor self-injection devices in chronic care bundles
Digital Health Initiatives	Support for connected health devices
FDA’s Breakthrough Device Program	Potential pathway for expedited approval
EU MDR & US FDA Regulations	Emphasis on post-market surveillance and safety standards

Key Influencers for Investment Decisions

• Market growth trajectory driven by chronic disease prevalence.
• Regulatory environment favoring innovation.
• Technological differentiation and alignment with digital health.
• Partnership and licensing opportunities with pharma and device companies.

---

Key Takeaways

• DAWNZERA holds significant market opportunity amid rising demand for patient-friendly self-injection devices.
• Competitive differentiation through technological innovation and connectivity is critical.
• Regulatory pathways in major regions are defined but require strategic navigation.
• Financial forecasts indicate rapid growth, with potential valuation surpassing $2 billion by 2027 if milestones are met.
• Investment risks include regulatory delays, intense competition, and manufacturing challenges, requiring proactive strategies.

---

FAQs

1. What distinguishes DAWNZERA from current autoinjectors?
DAWNZERA aims to incorporate advanced ergonomic design, digital connectivity, and minimal needle exposure, providing a superior patient experience and real-time health data integration to healthcare providers.

2. What are the main regulatory hurdles for DAWNZERA?
Approval depends on demonstrating device safety and efficacy aligned with regional standards (e.g., FDA, EMA). The most critical hurdles include clinical validation, biocompatibility testing, and post-market surveillance compliance.

3. How does market competition impact DAWNZERA's investment prospects?
While established players dominate certain segments, differentiation through innovation and digital integration allows DAWNZERA to capture niche markets and expand rapidly, enhancing investment returns.

4. What is the financial outlook for DAWNZERA within five years?
Projected revenues could reach USD 500 million, with valuation exceeding USD 2 billion, subject to successful clinical validation, regulatory approval, and effective market penetration.

5. What strategic partnerships could influence DAWNZERA's success?
Partnerships with biotech firms, pharmaceutical companies, and healthcare digital platforms are crucial for scaling manufacturing, expanding distribution, and enhancing product features.

---

References

[1] MarketsandMarkets, Autoinjectors Market by Application, End User & Geography, 2022.
[2] Fact.MR, Self-Injection Devices Market Forecast, 2022.